Belite Bio posted a net loss of $16.3M in Q2 2025 compared to a $9.5M loss last year, driven by increased R&D and G&A costs tied to its Phase 3 trials and share-based compensation. The company ended the quarter with $149.2M in cash and equivalents, and achieved key clinical milestones including full enrollment in the PHOENIX trial and Breakthrough Therapy Designation for Tinlarebant in Stargardt disease.

Kymera Therapeutics reported a net loss of $65.6 million for the first quarter of 2025, compared to $48.6 million in the same period last year. Collaboration revenues significantly increased to $22.1 million, primarily due to a $20 million milestone payment from the Sanofi collaboration. The company maintains a strong cash position of $775 million, extending its cash runway into the first half of 2028.

Kymera Therapeutics reported collaboration revenues of $7.4 million for Q4 2024. The company's research and development expenses were $71.8 million, and general and administrative expenses were $16.3 million. Net loss for the quarter was $70.8 million. The company's cash and cash equivalents totaled $851 million as of December 31, 2024.